

Dear REMAP-CAP investigators,

What a start to 2021! With five platform conclusions and more to come, we have shown that we are producing great science and research together. REMAP-CAPs contributions are the result of many people collaborating and going the extra mile to deliver research during this global pandemic.

Thank you for all your hard work and being part of the REMAP-CAP family. Together, we are really making a difference!

Lennie Derde, European Coordinating Investigator

Trial Inclusion Update

We are proud to announce that REMAP-CAP is currently (1st Feb 2021) active in **296** sites in **18** countries worldwide and a total of **6,001** unique patients have been included, of which **5,211** COVID-19 patients. These patients contributed to a total of **11,215** randomizations in the different domains.



Europe

- 197 Active sites
- 4,528 Patient Inclusions
- 4,308 COVID-19 Patients
- 9,022 Randomizations

WE4YOU

Join us for a bi-weekly update **every other Wednesday at 4 pm CET.**

We present different aspects of COVID-19, the REMAP-CAP domains, and a general Q&A session to share experiences with your fellow investigators. You can watch previous webinars [here](#).

The next WE4YOU takes place this **February 3rd 2021: The Mechanical Ventilation Domain with Alistair Nichol**

If there is any aspect you want to learn or talk about, let us know! Feel free to contact us directly at eu.remapcap@umcutrecht.nl.

Like listening to a **podcast**? Find our podcast series in collaboration with Rob Mac Sweeney from Critical Care Reviews on **Spotify and iTunes**:

1. **Steve Webb**, Monash University Melbourne, describes the **origins of REMAP-CAP** and the constant addition of new investigators and sites to the REMAP-CAP Family
2. **Scott Berry**, Berry Consulting, explains the **Bayesian framework** underlying the groundbreaking trial design
3. **Srin Murthy**, University of British Columbia Vancouver, and **John Marshall**, St. Michael's Hospital Toronto, discuss **the interventions** on the REMAP-CAP menu
4. **Mathias Pletz**, Jena University Hospital, describes **pandemics** and the role of the REMAP-CAP trial in combating the current pandemic





Chris Seymour and Lennie Derde join Howard Bauchner for a chat about the latest insights in critical care management of COVID-19 [here](#).

Available Domains

New domains are being launched and novel therapies on the REMAP platform are being evaluated. Here, we give an update on the REMAP-CAP menu:

Vitamin C: Investigating high dose vitamin C for all hospitalized CAP patients

Mechanical Ventilation*: Comparing Clinician Preferred with Guideline Recommended

COVID-19 Simvastatin:** Investigating the effect of simvastatin

COVID-19 Antiplatelet:** Comparing no Antiplatelet with Aspirin and P2Y12 inhibitor

COVID-19 ACE2 RAS:** Investigating the efficacy of ACE inhibitors or ARBs in the treatment of COVID-19

COVID-19 Antiviral:** Investigating the efficacy of ivermectin in the treatment of COVID-19

* CAP & COVID Severe

** COVID Severe & COVID Moderate

For questions and our social media go to:



eu.remapcap@umcutrecht.nl



[@remapcap](https://www.instagram.com/remapcap)



[@remap_cap](https://twitter.com/remap_cap)



[REMAP-CAP](#)

Announcements

IL-6 receptor antagonists effective in reducing deaths and organ support for ICU patients receiving organ support

Tocilizumab and sarilumab reduce mortality by 8.5% in critically ill COVID-19 patients receiving organ support. Furthermore, the treatment improved recovery so that on average patients were able to be discharged from the ICU about 7 days earlier compared to patients who received no immune modulator.

7 January 2021 *MedRxiv*

[Access Preliminary Report here](#)

Anticoagulation in COVID-19: the story continues

Recently, REMAP-CAP concluded that among critically ill patients with COVID-19, therapeutic anticoagulation did not improve outcomes. Only weeks later, we announced that these full doses of heparin were superior to "standard dose" thromboprophylaxis in hospitalized patients with COVID-19 not admitted to ICU. We are working hard with our partners from the ACTIV-4 and ATTACC studies to make the results public. A detailed presentation of the interim results can be found [here](#). We are rebuilding the COVID-19 anticoagulation domain to continue to answer pressing questions in this field in the study.

Convalescent Plasma: another one bites the dust

Recently, REMAP-CAP concluded that CP did not improve outcomes for critically ill patients with COVID-19. The results are being analyzed and will be made public asap.

